Panagiotis Balermpas

List of Publications by Citations

102 papers	1,713 citations	22 h-index	38 g-index
132 ext. papers	2,406 ext. citations	3.9 avg, IF	4.53 L-index

#	Paper	IF	Citations
102	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). *International Journal of Cancer*, **2016**, 138, 171-81	7.5	137
101	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. *Scientific Reports*, **2017**, 7, 13206	4.9	119
100	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 618-627	4	107
99	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Radiotherapy and Oncology*, **2014**, 113, 317-23	5.3	100
98	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. *Clinical Cancer Research*, **2016**, 22, 2639-49	12.9	88
97	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Radiotherapy and Oncology*, **2016**, 121, 364-373	5.3	80
96	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *International Journal of Cancer*, **2017**, 141, 594-603	7.5	57
95	Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. *International Journal of Cancer*, **2015**, 136, 278-88	7.5	55
94	Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. *OncoImmunology*, **2017**, 6, e1288331	7.2	53
93	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. *OncoImmunology*, **2014**, 3, e27403	7.2	46
92	Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. *Strahlentherapie Und Onkologie*, **2009**, 185, 775-81	4.3	37
91	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. *Clinical Cancer Research*, **2018**, 24, 1364-1374	12.9	32
90	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *International Journal of Cancer*, **2018**, 142, 1911-1925	7.5	32
89	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. *PLoS ONE*, **2018**, 13, e0198692	3.7	31
88	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. *European Journal of Cancer*, **2019**, 116, 67-76	7.5	29
87	Anal squamous cell carcinoma - State of the art management and future perspectives. *Cancer Treatment Reviews*, **2018**, 65, 11-21	14.4	29
86	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 **2020**, 8,		28

85	S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up. *JDDG - Journal of the German Society of Dermatology*, **2019**, 17, 214-230	1.2	26
84	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. *British Journal of Cancer*, **2018**, 118, 785-792	8.7	25
83	Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, e377-83	4	25
82	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. *Cancers*, **2019**, 11,	6.6	22
81	Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis. *Strahlentherapie Und Onkologie*, **2018**, 194, 143-155	4.3	22
80	Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges. *Radiation Oncology*, **2017**, 12, 82	4.2	22
79	Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. *BioMed Research International*, **2018**, 2018, 3508795	3	21
78	Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. *Strahlentherapie Und Onkologie*, **2015**, 191, 656-64	4.3	20
77	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. *Radiotherapy and Oncology*, **2018**, 126, 125-131	5.3	20
76	Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. *Melanoma Research*, **2019**, 29, 187-195	3.3	20
75	Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. *Frontiers in Oncology*, **2018**, 8, 171	5.3	18
74	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. *Frontiers in Immunology*, **2017**, 8, 1225	8.4	18
73	Treatment plan quality during online adaptive re-planning. *Radiation Oncology*, **2020**, 15, 203	4.2	18
72	S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis. *JDDG - Journal of the German Society of Dermatology*, **2019**, 17, 94-103	1.2	18
71	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 221-230	11.2	16
70	Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease. *Strahlentherapie Und Onkologie*, **2016**, 192, 25-31	4.3	15
69	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. *Frontiers in Oncology*, **2019**, 9, 20	5.3	14
68	Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	14

67	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. *Clinical and Translational Radiation Oncology*, **2017**, 5, 28-36	4.6	14
66	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. *Radiotherapy and Oncology*, **2020**, 151, 314-321	5.3	14
65	Dimethylfumarate Inhibits Colorectal Carcinoma Cell Proliferation: Evidence for Cell Cycle Arrest, Apoptosis and Autophagy. *Cells*, **2019**, 8,	7.9	13
64	Radiomic biomarkers for head and neck squamous cell carcinoma. *Strahlentherapie Und Onkologie*, **2020**, 196, 868-878	4.3	12
63	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. *Radiotherapy and Oncology*, **2018**, 127, 27-35	5.3	12
62	Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. *Radiotherapy and Oncology*, **2020**, 144, 209-217	5.3	11
61	Nuclear NF-B expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 785-90	4	11
60	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. *Scientific Reports*, **2020**, 10, 15625	4.9	11
59	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. *Cancers*, **2020**, 12,	6.6	11
58	Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. *Radiation Oncology*, **2017**, 12, 138	4.2	9
57	C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. *Frontiers in Oncology*, **2019**, 9, 1200	5.3	9
56	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. *OncoImmunology*, **2019**, 8, 1614858	7.2	8
55	RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. *Clinical and Translational Radiation Oncology* , **2020**, 23, 43-49	4.6	8
54	MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges. *Frontiers in Oncology*, **2021**, 11, 616156	5.3	8
53	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1871, 126-137	11.2	8
52	Combined proton-photon treatments - A new approach to proton therapy without a gantry. *Radiotherapy and Oncology*, **2020**, 145, 81-87	5.3	7
51	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. *Oncotarget*, **2016**, 7, 53339-53349	3.3	7
50	Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. *BMC Cancer*, **2020**, 20, 933	4.8	7

49	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. *Cancers*, **2021**, 13,	6.6	7
48	S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik. *JDDG - Journal of the German Society of Dermatology*, **2019**, 17, 94-104	1.2	6
47	A Bayesian network model of lymphatic tumor progression for personalized elective CTV definition in head and neck cancers. *Physics in Medicine and Biology*, **2019**, 64, 165003	3.8	6
46	S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und Nachsorge. *JDDG - Journal of the German Society of Dermatology*, **2019**, 17, 214-231	1.2	6
45	Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO). *Strahlentherapie Und Onkologie*, **2018**, 194, 750-758	4.3	6
44	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis. *Strahlentherapie Und Onkologie*, **2017**, 193, 305-314	4.3	5
43	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. **2022**, 10,		5
42	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. *Oral Oncology*, **2020**, 111, 104931	4.4	5
41	Head and neck radiotherapy on the MR linac: a multicenter planning challenge amongst MRIdian platform users. *Strahlentherapie Und Onkologie*, **2021**, 197, 1093-1103	4.3	5
40	Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. *International Journal of Cancer*, **2021**, 149, 358-370	7.5	5
39	Analysis of lymphatic metastasis and progression patterns for clinical target volume (CTV) definition in head and neck squamous cell carcinoma (HNSCC). *Acta Oncologica*, **2019**, 58, 1519-1522	3.2	4
38	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. *Radiotherapy and Oncology*, **2018**, 126, 214-221	5.3	4
37	Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.. *Journal of Clinical Oncology*, **2021**, 39, 6007-6007	2.2	4
36	A hidden Markov model for lymphatic tumor progression in the head and neck. *Scientific Reports*, **2021**, 11, 12261	4.9	4
35	Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. *Oncology Letters*, **2014**, 7, 534-540	2.6	3
34	Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.. *Journal of Clinical Oncology*, **2017**, 35, 6016-6016	2.2	3
33	Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy. *Physics and Imaging in Radiation Oncology*, **2021**, 17, 43-46	3.1	3
32	A pattern of care analysis: Prosthetic rehabilitation of head and neck cancer patients after radiotherapy. *Clinical Implant Dentistry and Related Research*, **2020**, 22, 333-341	3.9	2

31	A clinical example of extreme dose exposure for an implanted cardioverter-defibrillator : Beyond the DEGRO guidelines. *Strahlentherapie Und Onkologie*, **2017**, 193, 756-760	4.3	2
30	Dental extraction, intensity-modulated radiotherapy of head and neck cancer, and osteoradionecrosis : A systematic review and meta-analysis.. *Strahlentherapie Und Onkologie*, **2022**, 198, 219	4.3	2
29	Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. *Radiation Oncology*, **2021**, 16, 217	4.2	2
28	Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. *European Archives of Oto-Rhino-Laryngology*, **2021**, 278, 4411-4421	3.5	2
27	Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2) of >180 Gy for patients with recurrent head and neck cancer. *Head and Neck*, **2019**, 41, E48-E54	4.2	2
26	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. *Pharmacogenomics Journal*, **2021**, 21, 37-46	3.5	2
25	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. *Clinical and Translational Radiation Oncology*, **2021**, 26, 62-70	4.6	2
24	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). *Scientific Reports*, **2021** , 11, 4590	4.9	2
23	Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice. *Strahlentherapie Und Onkologie*, **2021**, 1	4.3	2
22	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG.. *Radiotherapy and Oncology*, **2022**,	5.3	2
21	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. *Journal of Molecular Diagnostics*, **2020**, 22, 801-810	5.1	1
20	Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.. *Radiotherapy and Oncology*, **2022**,	5.3	1
19	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. *Journal of Clinical Oncology*, **2018**, 36, 6047-6047	2.2	1
18	Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. *Scientific Reports*, **2021**, 11, 20890	4.9	1
17	MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. *Cancers*, **2021**, 13,	6.6	1
16	Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. *Radiation Oncology*, **2021**, 16, 64	4.2	1
15	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. *Clinical and Translational Radiation Oncology*, **2021**, 28, 71-78	4.6	1
14	The Role of Regional Disease and Patterns of Treatment Failure in Primary Sinonasal Malignancies. *American Journal of Rhinology and Allergy*, **2022**, 36, 157-166	2.4	1

List of Publications

13	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial.. *Frontiers in Oncology*, **2022**, 12, 817692	5.3	1
12	A dataset on patient-individual lymph node involvement in oropharyngeal squamous cell carcinoma. *Data in Brief*, **2022**, 108345	1.2	1
11	Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. *Journal of Clinical Oncology*, **2018**, 36, 6019-6019	2.2	0
10	A 2.5D convolutional neural network for HPV prediction in advanced oropharyngeal cancer.. *Computers in Biology and Medicine*, **2022**, 142, 105215	7	0
9	Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID-19 pandemic. *Laryngoscope Investigative Otolaryngology*, **2021**, 6, 904-910	2.8	0
8	FDG-PET/CT for oral focus assessment in head and neck cancer patients.. *Clinical Oral Investigations*, **2022**, 1	4.2	0
7	Anti-EGFR-Therapie in Kombination mit Radiotherapie f Patienten mit Kopf-Hals-Karzinomen doch keine therapeutische Revolution. *Strahlentherapie Und Onkologie*, **2015**, 191, 619-622	4.3	
6	Reply to: Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. *Strahlentherapie Und Onkologie*, **2015**, 191, 986	4.3	
5	Doch keine therapeutische Revolution beim Kopf-Hals-Karzinom. *Info Onkologie*, **2015**, 18, 25-26		
4	Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. *International Journal of Cancer*, **2021**, 150, 603	7.5	
3	Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. *Journal of Clinical Oncology*, **2019**, 37, 6050-6050	2.2	
2	Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.. *Journal of Clinical Oncology*, **2016**, 34, 6056-6056	2.2	
1	Pediatric CNS imaging and long-term effects of irradiation in pediatric oncology patients. *Pediatrics International*, **2021**, 63, 81-87	1.2	